FDA Approves Perrigo’s AB Rated Generic Version Of Topicort® Spray, 0.25%

Perrigo Company has received U.S. Food and Drug Administration approval for its first-to-file Abbreviated New Drug Application referencing Taro Pharmaceuticals USA Inc.'s Topicort^®Spray, 0.25% (desoximetasone topical spray, 0.25%).  Prior patent litigation between the companies has been settled on confidential terms.  

Topicort^® Spray, 0.25% (desoximetasone topical spray, 0.25%) is a corticosteroid indicated for the treatment of plaque psoriasis in patients 18 years of age or older and had estimated sales for the twelve months ending November 2016 of $24 million. 

Perrigo's CEO John T. Hendrickson stated, "The ability to develop and bring to market difficult formulations such as this one is what differentiates Perrigo's Rx employees and portfolio and furthers our offerings to customers around the globe."